LTQ Orbitrap XL ETD mass spectrometer

描述（由申请人提供）：肯塔基大学（英国）医学院蛋白质组学核心设施申请947163美元，用于购买LTQ Orbitrap XL/ETD混合质谱仪和Eksigent纳米高效液相色谱。该应用程序的目标是提供先进的质谱分析能力，以满足19位高生产力的美国国立卫生研究院资助的英国研究人员的蛋白质组学需求。LTQ Orbitrap/ETD混合质谱仪是一种新型线性离子阱（LTQ）、新型高精度静电离子阱（Orbitrap）质谱仪和创新的电子转移解离（ETD）技术的结合。与现有的蛋白质和肽分析质谱仪相比，该混合仪器在单次实验中同时提供高灵敏度（原子摩尔）、高光谱重复率、高质量分辨率（60,000 HWFM）、高质量精度（< 5ppm）和互补碎片化技术（CID和ETD）。该仪器达到了一个新的水平的敏感性和信心，以识别肽和蛋白质。此外，ETD技术具有多种独特的优势。特别是它可以保存多肽在断裂过程中的翻译后修饰，并允许鉴定准确的修饰位点。该设备将为蛋白质组学核心设施提供最先进的能力，并提高该设施的能力，以满足不断增加的研究支持的数量和强度。该设备对于这些正在进行的研究项目以及在蛋白质鉴定、翻译后修饰表征、基因发现和功能蛋白质组学方面刺激和实现新的合作研究计划至关重要。目前，在英国或肯塔基州联邦的任何大学都没有LTQ Orbitrap/ETD质谱仪。该仪器的购买对于英国在人类疾病和基础研究方面的蛋白质组学研究项目的持续扩展和加强至关重要。如本申请所述，来自12个不同部门的19名美国国立卫生研究院资助的研究人员对该质谱仪有特定需求。所要求的仪器将对我们机构的研究能力产生重大影响。为了确保最大限度的使用和适当的维护，仪器将被安置在PI实验室旁边的蛋白质组学核心中。PI在生物质谱/蛋白质组学领域拥有超过10年的经验。成立了一个由内部和外部成员组成的咨询委员会，为共同文书的使用提供全面指导。大学承诺为仪器的长期维护和运行提供资金支持。该仪器支持的研究涵盖了广泛的生物学和生物医学研究，包括专注于神经系统疾病、癌症、糖尿病、心血管疾病、病毒学、眼病和妇女健康的前沿项目。英国医学中心蛋白质组学核心设施的这台仪器将显著提高这些研究项目的生产力和进展，从而推进NIH改善公众健康的使命。该提案的资金将导致雇用或保留超过6个全职职位，其中包括肯塔基大学的至少1个，赛默飞世尔科学公司的4个，以及Eksigent技术公司的1个。因此，该提案符合《复苏法案》拨款的标准。该仪器的制造商（赛默飞世尔科技公司和爱克sigent科技公司）致力于对环境负责。尤其值得一提的是，与其他分离式色谱仪器相比，Eksigent Technologies生产的无分裂纳米高效液相色谱仪使用的有机溶剂显著减少，因此产生的化学废物减少了数百至数千倍。此外，将由所要求的仪器启用和支持的生物医学研究项目将做出有助于改善美国人健康的发现。总之，这项应用的资金将使美国和世界更健康、更清洁、更安全。

DESCRIPTION (provided by applicant): The Proteomics Core Facility at the University of Kentucky (UK) College of Medicine requests $947,163 to acquire a LTQ Orbitrap XL/ETD hybrid mass spectrometer with an Eksigent nano-HPLC. The goal of this application is to provide advanced mass spectrometry capabilities to meet the proteomics needs of 19 highly productive NIH-funded investigators at UK. The LTQ Orbitrap/ETD hybrid mass spectrometer is a combination of a new linear ion trap (LTQ), a novel and high precision electrostatic ion trap (Orbitrap) mass analyzer, and innovative electron transfer dissociation (ETD) technology. In comparison to the existing mass spectrometers for protein and peptide analysis, this hybrid instrument simultaneously provides high sensitivity (attomoles), high spectrum repetition rates, high mass resolution (60,000 HWFM), high mass accuracy (< 5ppm), and complementary fragmentation techniques (both CID and ETD) during a single experiment. The instrumentation reaches a new level of sensitivity and confidence for identifying peptides and proteins. Moreover, the ETD technology provides multiple unique advantages. Particularly it can preserve the post-translation modifications on peptides during fragmentation and allow the identification of exact modification sites. This equipment will provide state-of-the-art capabilities to the Proteomics Core Facility and enhance the ability of the facility to meet an ever-increasing volume and intensity of research support. This equipment is essential to these ongoing research programs and to stimulating and enabling new collaborative research initiatives on protein identification, posttranslational modification characterization, gene discovery, and functional proteomics. Currently, there is no LTQ Orbitrap/ETD mass spectrometer at UK or any universities in the Commonwealth of Kentucky. The purchase of the instrument is critical to the continuing expansion and enhancement of the proteomics research program in human disease and basic research at UK. As described in this application, 19 NIH-funded investigators from 12 different departments have specific needs for this mass spectrometer. The requested instrument will have a major impact on research capabilities at our institution. To ensure the maximal usage and proper maintenance, the instrument will be housed in the Proteomics Core next to the laboratory of the PI. The PI has over 10 years experience in the area of biological mass spectrometry/proteomics. An Advisory Committee with both internal and external members is assembled for overall guidance for the usage of the shared instrument. Financial support for the long term maintenance and operation of the instrument is committed from the University. The research to be supported by this instrument spans a wide spectrum of biological and biomedical research, including cutting-edge programs focused on neurological disorders, cancer, diabetes, cardiovascular disease, virology, eye diseases, and women's health. The addition of this instrument to the Proteomics Core Facility at UK Medical Center will significantly enhance the productivity and progress of these research programs, thus advancing the NIH mission to improve public health. The funding of this proposal will lead to the hiring and/or retention of more than six full-time positions, including at least one in the University of Kentucky, four at Thermo Fisher Scientific, and one with Eksigent Technologies. Thus this proposal fits the criteria for Recovery Act funding. The manufacturers of the instrumentation (Thermo Fisher Scientific and Eksigent Technologies) are committed to being environmentally responsible. In particular, the splitless nano-HPLC manufactured by Eksigent Technologies uses significantly less organic solvents compared to other split-flow chromatography instruments, thus generating hundreds- to thousands-fold less chemical waste. Moreover, the biomedical research programs that will be enabled and supported by the requested instrumentation will make discoveries leading to better health of Americans. In summary, the funding of this application will make the United States and the world healthier, cleaner and safer. PUBLIC HEALTH RELEVANCE: The Proteomics Core Facility at the University of Kentucky (UK) College of Medicine requests $947,163 to acquire a LTQ Orbitrap XL ETD hybrid mass spectrometer with an Eksigent nano-HPLC. The goal of this application is to provide advanced mass spectrometry capabilities to meet the proteomics needs of 19 highly productive NIH-funded investigators at UK. The research to be supported by this instrument spans a wide spectrum of biological and biomedical research, including cutting-edge programs focused on neurological disorders, cancer, diabetes, cardiovascular disease, virology, eye diseases, and women's health. The addition of this instrument to the Proteomics Core Facility will significantly enhance the productivity and progress of these research programs, thus advancing the NIH mission to improve public health. The funding of this proposal will lead to the hiring and/or retention of more than six full-time positions, meeting the intention of the Recovery Act. The requested instruments are environmentally friendly. In summary, the funding of this application will make the United States and the world healthier, cleaner and safer.